|
1.
|
|
|
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial
/
Iveson, Timothy J (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ;
Kerr, Rachel S (Department of Oncology, University of Oxford, Oxford, UK) ;
Saunders, Mark P (The Christie Hospital, Manchester, UK) ;
Cassidy, Jim (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Hollander, Niels Henrik (Department of Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark) ;
Tabernero, Josep (VHIO) ;
Haydon, Andrew (Australasian Gastro-Intestinal Trials Group, Melbourne, VIC, Australia) ;
Glimelius, Bengt (IGP, University of Uppsala, Uppsala, Sweden) ;
Harkin, Andrea (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Allan, Karen (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
McQueen, John (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Scudder, Claire (OCTO, University of Oxford, Department of Oncology, Oxford, UK) ;
Boyd, Kathleen Anne (Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK) ;
Briggs, Andrew (Center for Health and Policy Outcomes, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Centre, New York, NY, USA) ;
Waterston, Ashita (Beatson West of Scotland Cancer Centre, Glasgow UK) ;
Medley, Louise (Royal United Hospital, Bath, UK) ;
Wilson, Charles (Addenbrookes Hospital, Cambridge, UK) ;
Ellis, Richard (Royal Cornwall Hospital NHS Trust, Truro, UK) ;
Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK) ;
Dhadda, Amandeep S (Castle Hill Hospital, Hull, UK) ;
Harrison, Mark (Mount Vernon Cancer Centre, Northwood, UK) ;
Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ;
Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ;
Rees, Charlotte (Southampton University Hospital NHS Foundation Trust, Southampton, UK) ;
Olesen, Rene K (Department of Oncology, Aarhus University Hospital, Aarhus, Denmark) ;
Propper, David (Barts Cancer Institute, Queen Mary University of London, London, UK) ;
Bridgewater, John (UCL Cancer Institute, University College London, London UK) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK) ;
Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK) ;
Webb, Andrew (Brighton and Sussex University Hospital Trust, Brighton, UK) ;
Cunningham, David (Royal Marsden Hospital, London, UK) ;
Hickish, Tamas (Poole Hospital, Bournemouth University, Bournemouth, UK) ;
Weaver, Andrew (Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK) ;
Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ;
Wasan, Harpreet S (Hammersmith Hospital, Imperial College London, London, UK) ;
Paul, James (Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) ;
Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. [...]
2018 -  10.1016/S1470-2045(18)30093-7
The Lancet. Oncology, Vol. 19 (april 2018) , p. 562-578
|
|
|
2.
|
|
19 p, 418.6 KB |
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer : Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
/
Van Cutsem, Eric (University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium) ;
Huijberts, Sanne (Netherlands Cancer Institute, Amsterdam, the Netherlands) ;
Grothey, Axel (West Cancer Center, Germantown, TN) ;
Yaeger, Rona (Memorial Sloan Kettering Cancer Center, New York, NY) ;
Cuyle, Pieter-Jan (Imelda General Hospital, Bonheiden, Belgium; University Hospitals Gasthuisberg, Leuven, Belgium) ;
Elez, Elena (VHIO) ;
Fakih, Marwan (City of Hope Comprehensive Cancer Center, Duarte, CA) ;
Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Peeters, Marc (Antwerp University Hospital, Edegem, Belgium) ;
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Wasan, Harpreet (Hammersmith Hospital, Imperial College London, London, United Kingdom) ;
Desai, Jayesh (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) ;
Ciardiello, Fortunato (University of Campania "Luigi Vanvitelli," Naples, Italy) ;
Gollerkeri, Ashwin (Array BioPharma Inc, Boulder, CO) ;
Christy-Bittel, Janna (Array BioPharma Inc, Boulder, CO) ;
Maharry, Kati (Array BioPharma Inc, Boulder, CO) ;
Sandor, Victor (Array BioPharma Inc, Boulder, CO) ;
Schellens, Jan H.M. (Utrecht University, Utrecht, the Netherlands) ;
Kopetz, Scott (The University of Texas MD Anderson Cancer Center, Houston, TX) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
VHIR Vall d'Hebron Institut de Recerca
To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial ( identifier: ; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). [...]
2019 - 10.1200/JCO.18.02459
Journal of Clinical Oncology, Vol. 37 (march 2019) , p. 1460-1469
|
|
|
3.
|
|
7 p, 1.3 MB |
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
/
Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ;
Garcia-Carbonero, Rocio (Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain) ;
Macarulla, Teresa (VHIO) ;
Pezet, Denis (Centre Hospitalier Universitaire) ;
Deplanque, Gael (Hôpital Riviera-Chablais) ;
Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ;
Trojan, Jorg (Goethe University Medical Center) ;
Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ;
Kozloff, Mark (Ingalls Memorial Hospital) ;
Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Smith, Claire (formerly of Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ;
Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ;
Blunt, Al (Advaxis, Inc) ;
Benhadji, Karim A. (Eli Lilly and Company) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214
|
|
|
4.
|
|
9 p, 297.7 KB |
New clinical trial designs in the era of precision medicine
/
Garralda, Elena (Universitat Autònoma de Barcelona) ;
Dienstmann, Rodrigo (Universitat Autònoma de Barcelona) ;
Piris-Giménez, Alejandro (Universitat Autònoma de Barcelona) ;
Braña, Irene (Universitat Autònoma de Barcelona) ;
Rodon Ahnert, Jordi (Universitat Autònoma de Barcelona) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Universitat Autònoma de Barcelona ;
VHIO Vall d'Hebron Institut d'Oncologia
Cancer treatment has made significant strides towards the promise of personalized medicine. Recent scientific advances have shown that there are numerous genetic deregulations that are common in multiple cancer types, raising the possibility of developing drugs targeting those deregulations irrespective of the tumour type. [...]
2019 - 10.1002/1878-0261.12465
Molecular Oncology, Vol. 13 (february 2019) , p. 549-557
|
|
|
5.
|
|
7 p, 434.6 KB |
SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
/
Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ;
Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ;
Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ;
Iveson, Timothy (Southampton University Hospital NHS Foundation Trust) ;
Kerr, Rachel S. (University of Oxford. Department of Oncology) ;
Saunders, Mark P. (The Christie Hospital) ;
Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Hollander, Niels Henrik (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ;
Glimelius, Bengt (University of Uppsala) ;
Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ;
Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ;
Waterston, Ashita (Beatson West of Scotland Cancer Centre) ;
Medley, Louise (Royal United Hospital) ;
Wilson, Charles (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ;
Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ;
Dhadda, Amandeep S. (Castle Hill Hospital) ;
Hughes, Rob (Mount Vernon Cancer Centre) ;
Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ;
Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ;
Rees, Charlotte (Southampton University Hospital NHS Foundation Trust) ;
Olesen, Rene K (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ;
Propper, David (Queen Mary, University of London. Barts Cancer Institute) ;
Bridgewater, John (University College London) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ;
Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ;
Webb, Andrew (Brighton and Sussex University Hospital Trust) ;
Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ;
Hickish, Tamas (Poole Hospital/Bournemouth University) ;
Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ;
Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ;
Wasan, Harpreet S (Hammersmith Hospital, Imperial College London) ;
Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 - 10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338
|
|
|
6.
|
|
11 p, 542.8 KB |
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
/
Reynolds, Kerry Lynn ;
Bedard, Philippe L. (Toronto, ON Canada) ;
Lee, Se-Hoon (Seoul, Republic of Korea) ;
Lin, Chia-Chi (Taipei, Taiwan) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Alsina, Maria (Hospital Universitari Vall d'Hebron) ;
Cohen, Ezra (La Jolla, CA USA) ;
Baselga Torres, Josep, 1959-2021, (New York, NY USA) ;
Blumenschein, George (Houston, TX USA) ;
Graham, Donna M. (Toronto, ON Canada) ;
Garrido-Laguna, Ignacio (Salt Lake City, UT USA) ;
Juric, Dejan (Fruit Street, Boston, MA 02114 USA) ;
Sharma, Sunil (Salt Lake City, UT USA) ;
Salgia, Ravi (Duarte, CA USA) ;
Seroutou, Abdelkader (Basel, Switzerland) ;
Tian, Xianbin (East Hanover, NJ USA) ;
Fernandez, Rose (East Hanover, NJ USA) ;
Morozov, Alex (New York, NY USA) ;
Sheng, Qing (Cambridge, MA USA) ;
Ramkumar, Thiruvamoor (East Hanover, NJ USA) ;
Zubel, Angela (Basel, Switzerland) ;
Bang, Yung-Jue (Seoul, Republic of Korea) ;
Universitat Autònoma de Barcelona
Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. [...]
2017 - 10.1186/s12885-017-3641-6
BMC Cancer, Vol. 17 (september 2017)
|
|
|
7.
|
|
6 p, 1.4 MB |
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients
/
Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Lampis, Andrea (The Institute of Cancer Research. Department of Molecular Pathology) ;
Hahne, Jens Claus (The Institute of Cancer Research. Department of Molecular Pathology) ;
Ghidini, Michele (The Institute of Cancer Research. Department of Molecular Pathology) ;
Lote, Hazel (The Institute of Cancer Research. Department of Molecular Pathology) ;
Zito, Domenico (The Institute of Cancer Research. Department of Molecular Pathology) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Glimelius, Bengt (University of Uppsala. Genetics and Pathology, Experimental and Clinical Oncology. Department of Immunology) ;
Cervantes, Andres (University of Valencia. Biomedical Research Institute INCLIVA. Department of Haematology and Medical Oncology) ;
Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Wilson, Sanna Hulkki (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Peckitt, Clare (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Tait, Diana (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Oates, Jacqueline (The Royal Marsden NHS Foundation Trust. Department of Medicine) ;
Braconi, Chiara (The Institute of Cancer Research. Department of Cancer Therapeutics) ;
Valeri, Nicola (The Institute of Cancer Research. Department of Molecular Pathology) ;
Universitat Autònoma de Barcelona
Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab. [...]
2016 - 10.1093/carcin/bgw073
Carcinogenesis, Vol. 37 (july 2016) , p. 852-857
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
